title: Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators.
abstract: OBJECTIVE
  Drug treatment of high blood pressure has been shown to reduce the associated cardiovascular risk. Stroke represents the type of event more strongly linked with high blood pressure, responsible for a high rate of death or invalidity, and with the highest proportion of events that can be avoided by treatment. Hypertensive patients with a history of cerebrovascular accident are at particularly high risk of recurrence. Specific trials of blood pressure lowering drugs in stroke survivors showed inconclusive results in the past.
  
  
  METHODS
  We performed a meta-analysis using all available randomized controlled clinical trials assessing the effect of blood pressure lowering drugs on clinical outcomes (recurrence of stroke, coronary events, cause-specific, and overall mortality) in patients with prior stroke or transient ischemic attack.
  
  
  RESULTS
  We identified 9 trials, including a total of 6752 patients: 2 trials included 551 hypertensive stroke survivors; 6 trials of hypertensive patients included a small proportion of stroke survivors (536 patients); 1 trial included stroke survivors, whether hypertensive or not (5665 patients). The recurrence of stroke, fatal and nonfatal, was significantly reduced in active groups compared with control groups consistently across the different sources of data (relative risk of 0.72, 95% confidence interval: 0.61 to 0.85). There was no evidence that this intervention induced serious adverse effect.
  
  
  CONCLUSIONS
  Blood pressure lowering drug interventions reduced the risk of stroke recurrence in stroke survivors. Available data did not allow to verify whether such benefit depends on initial blood pressure level. More data are needed before considering antihypertensive therapy in normotensive patients at high cerebrovascular risk.
authors.affiliation: Clinical Pharmacology Department, Claude Bernard University, Lyon Hospitals, France. fg@upcl.univ-lyon1.fr
authors.forename: F
authors.initials: F
authors.lastname: Gueyffier
authors.forename: J P
authors.initials: JP
authors.lastname: Boissel
authors.forename: F
authors.initials: F
authors.lastname: Boutitie
authors.forename: S
authors.initials: S
authors.lastname: Pocock
authors.forename: J
authors.initials: J
authors.lastname: Coope
authors.forename: J
authors.initials: J
authors.lastname: Cutler
authors.forename: T
authors.initials: T
authors.lastname: Ekbom
authors.forename: R
authors.initials: R
authors.lastname: Fagard
authors.forename: L
authors.initials: L
authors.lastname: Friedman
authors.forename: K
authors.initials: K
authors.lastname: Kerlikowske
authors.forename: M
authors.initials: M
authors.lastname: Perry
authors.forename: R
authors.initials: R
authors.lastname: Prineas
authors.forename: E
authors.initials: E
authors.lastname: Schron
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000150:complications* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D000959:Antihypertensive Agents